Autologous cytokine-induced killer (CIK) cells in the treatment of hematological malignancies

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNRC-11001806

Enrollment

Unknown

Registered

2011-12-14

Start date

2011-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies

Interventions

1:Autologous CIK cells

2:Routine supportive care

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. aged between 18 and 70 years, with a KPS score > 60 points and estimated survival time > 3 months; 2. With confirmed hematological malignancies after chemotherapy or hematopoietic stem cell transplantation, including lymphoma, leukemia, multiple myeloma, myelodysplastic syndrome (intermediate-risk II and poor-risk), myeloproliferative neoplasm and so on; 3. Without serious mental illness and serious heart, liver, kidney or pulmonary insufficiency, and other fatal diseases; 4. Agreed to participate in this study, and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Serious mental patient; 2. Serious heart, liver, kidney or pulmonary insufficiency; 3. Other fatal diseases; 4. In gestation period or suckling period; 5. HIV infection or substance abuse.

Design outcomes

Primary

Measure	Time frame
Immune index;Disease-free survival;Overall survival;	—

Countries

China

Contacts

Public ContactJieping Chen

chenjpxn@yahoo.com.cn+86 13983766908

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026